SURVYR
SC 13D · 5.9% STAKE Institutional Filing Alert

Starboard Value LP disclosed a 5.9% stake in KVUE

New 5.9% Schedule 13D activist stake targeting brand turnaround and margin restructuring.

KVUE

Kenvue Inc.
$19.43
−$0.07 (0.36%)Oct 27 close
Consumer StaplesS&P 500 CompareTechnicals
-7%+5%+17%+29%+42%Oct 2025Oct 2026Apr 202652w high $20.1352w low $14.02
KVUESPY
Wall St. Highest PT $23.00 (+18.4%) Wall St. Avg PT $19.50 (+0.4%)
$13$16$19$21$24POC $17Hi $23Avg $20
Underwater Drawdown %Max DD -12.5%Current -2.3%
0.0%-12.5%
Relative Strength vs SPY+23.1% vs SPYOutperforming
+34%0%-34%
1W
+$0.15 (0.78%)
1M
+$1.63 (9.16%)
3M
+$0.13 (0.66%)
6M
+$2.49 (14.71%)
YTD
+$2.96 (17.98%)
1Y
+$5.21 (36.66%)

Chart

Loading live chart…

Ratings & dials

1m · 5m · 15m · 1h · 4h · 1D

Analyst & Morningstar ratings

Consensus · Targets · Morningstar
Wall Street analyst consensus
SellHoldStrong Buy
Hold
12 analysts · mean score 2.79
1 = Strong Buy · 5 = Sell
Wall Street consensus
Analyst price targets
Current price$19.43
Average target$19.50
+$0.07 (+0.4%) upsideaverage target vs current price
CurrentAverageMedian
Low$18.00
Median$19.50
High$23.00
12-month Wall Street target range
Recent analyst rating changes · 8
Reiterated
2026-08-11 · UBS reiterated Neutral on KVUE
Reiterated
2026-07-21 · Barclays reiterated Equal-Weight on KVUE
Reiterated
2026-07-16 · UBS reiterated Neutral on KVUE
Reiterated
2026-04-15 · Citigroup reiterated Neutral on KVUE
Reiterated
2026-04-14 · Barclays reiterated Equal-Weight on KVUE
Reiterated
2026-04-07 · UBS reiterated Neutral on KVUE

Third-party ratings, not SURVYR.'s views.

Key stats & company

Market value$36.6B
P/E (last 12 months)22.1
P/E (next 12 months, estimated)15.4
52-week range$14.02 – $20.13
Revenue growth (latest quarter vs a year ago)+3.0%
Dividend yield4.36%
Analyst consensusHold (12)
Average analyst price target$19.50 (+0%)

What they do

Kenvue Inc. operates as a consumer health company in the United States, rest of North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates in three segments: Self Care, Skin Health and Beauty, and Essential Health. The company offers over-the-counter medicine for cough, cold and allergy, pain care, digestive health, smoking cessation, and eye care.

Consumer Defensive · Household & Personal Products
Valuation and fundamentals

Valuation & fundamentals

Loading the valuation from SEC filings…

For information only · Important disclosures

Grades vs sector

Momentum
86th percentile in sector
A-
12-1 return: +30.3%
Percentile within its GICS sector across the S&P 1500.
Growth
50th percentile in sector
C+
Revenue growth (YoY): +3.0%
Percentile within its GICS sector across the S&P 1500.
Value
45th percentile in sector
C
Forward E/P: 6.6% · EBITDA/EV: 7.9%
Percentile within its GICS sector across the S&P 1500.
Profitability
65th percentile in sector
B
Profit margin: +10.8% · Return on equity: +15.6%
Percentile within its GICS sector across the S&P 1500.
Revisions
Not enough data yet
–
EPS estimate change, 30 days (current FY): –
30-day change in analysts' current-year EPS estimate; graded across covered stocks.

Systematic Models

Not held by any of our 7 live models right now.

Quality Growth
Outside this model's universe or screens
Momentum Top 15
ranked 171 of 499 · 12-month momentum 21.9%
Momentum Blend
Not in the current book
New Highs Growth
Outside this model's universe or screens
SURVYR. Barbell Momentum & T-Bill Shield
Outside this model's universe or screens
SURVYR. Physical AI Grid & Power
Outside this model's universe or screens
SURVYR. Long Book
Not in the current book

Earnings & events

KVUE earningsNext report in 8 days
Next report
Thu Nov 5, 2026Before the open
EPS consensus$0.29 range $0.28–$0.32
Revenue consensus$3.9B 9 analysts
Last 4 quarters · EPS vs estimate
Aug 6, 2026$0.31est $0.32−2.8%Below estimates
May 7, 2026$0.32est $0.26+23.0%Above estimates
Feb 17, 2026$0.27est $0.22+21.2%Above estimates
Nov 3, 2025$0.28est $0.26+5.7%Above estimates

In line = within 1% of the estimate.

Source: Yahoo Finance · refreshed 2026-10-21 18:29:04 ET
24-1125-0225-0525-0825-1126-0226-0526-080.000.32
EstimateActual (beat)Actual (miss)

Quarterly revenue

QuarterRevenueYoY
2026-06-30$4.0B+3.0%
2026-03-31$3.9B–
2025-12-31$3.8B–
2025-09-30$3.8B–
2025-06-30$3.8B–

Recent dividends

2026-09-21: $0.210 · 2026-08-12: $0.210 · 2026-05-13: $0.208 · 2026-02-11: $0.208 · 2025-11-12: $0.208 · 2025-08-13: $0.208 · 2025-05-14: $0.205 · 2025-02-12: $0.205

News & catalysts

More news
Kenvue shares may move 5.7% on Oct. 30 earnings release
Investing.com · Oct 23
Johnson & Johnson Raised Its Dividend Every Year. Why Did It Trail the S&P 500?
24/7 Wall St. · Oct 21
Rating changes
Reiterated
2026-08-11 · UBS reiterated Neutral on KVUE
Reiterated
2026-07-21 · Barclays reiterated Equal-Weight on KVUE
Reiterated
2026-07-16 · UBS reiterated Neutral on KVUE
Reiterated
2026-04-15 · Citigroup reiterated Neutral on KVUE
Reiterated
2026-04-14 · Barclays reiterated Equal-Weight on KVUE
Reiterated
2026-04-07 · UBS reiterated Neutral on KVUE

Third-party analyst actions, not SURVYR.'s views. All rating changes

Insider trades
None
None · None
Sell
–
None
None · None
Sell
–
None
None · None
Sell
–
None
None · None
Sell
–
None
None · None
Sell
–
None
None · None
Sell
–
None
None · None
Sell
–
None
None · None
Sell
–
None
None · None
Sell
–
None
None · None
Sell
–

Stats refreshed 2026-10-21 18:29:04 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

Morning Brief (8 AM ET) & Market Close (4:30 PM ET), weekdays

Indexes, sectors, biggest movers, rates, top news, SURVYR. model changes and what's ahead. Free, two short emails each weekday.

Editions

Free. Not investment advice. Unsubscribe anytime.

SURVYR

Free to use. No card, no ads, no auto-renew.

Systematic research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app

Coteau 0.9 · Oct 21, 2026